What type of study is this?

This is a RCT study (also classified as: Phase 3).

October 8, 2025

Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial

AOAlexander OlawaiyeGynecologic Oncology Group LGLaurence GladieffInstitut Claudius Regaud DODavid M. O’MalleyThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Key Points

The trial shows promising results for relacorilant and nab-paclitaxel in treatment response among platinum-resistant ovarian cancer patients.
Approximately 70% of ovarian cancer patients exhibit resistance to platinum-based chemotherapy, indicating a need for alternative therapies.
This phase 3 trial evaluates new treatment options for ovarian cancer patients unresponsive to traditional platinum therapies.
Effective management of platinum-resistant ovarian cancer could significantly improve patient outcomes and survival rates.

Abstract

(Abstracted from Lancet 2025;405(10496):2205–2216) Deaths related to ovarian cancer were estimated at 207,000 in 2020 across the globe. An approximate 70% of patients have relapses of the disease after platinum-based chemotherapy as they develop resistance to the treatment; platinum-resistant ovarian cancer can be treated with nonplatinum chemotherapy with or without bevacizumab.

Ask AI

Helpful

Bookmark

View Full Paper